BioSpace News Archive

Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated positive results from an ongoing Phase 2 clinical trial evaluating its Rho-associated coiled-coil kinase 2 inhibitor, in patients with chronic graft-versus-host disease

OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating its investigational vaccine product PVX-410 for the treatment of patients with metastatic triple negative breast cancer (TNBC) who are human leukocyte antigen A2 positive (HLA-A2+).

Planet Innovation, a leading healthtech product design and commercialization company, today announced a partnership with Preora Healthcare Inc., pioneers in the detection of early-stage cancers, to bring to market a series of novel, low-cost, minimally invasive, highly accurate and easy-to-use cancer screening tests.

Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its financial results for the fourth quarter and full year ended December 31, 2017 on Thursday, March 1, 2018, after the U.S. stock markets close.

Leading oncologists from University of California, San Francisco (UCSF) will discuss latest research in gastrointestinal cancer.

“This preclinical demonstration that stent deployment of microcrystalline drug in combination with a rapidly absorbable polymer, such as with MiStent, results in more uniform drug dosing that could lead to more rapid and uniform healing across the treated segment,” said David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute, Atlanta.

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers evaluated the performance of noninvasive hemodynamic monitoring (NIHM) using Masimo noninvasive and continuous hemoglobin (SpHb®), as compared to invasive laboratory hemoglobin (LabHb) monitoring, in clinically stable pediatric trauma patients with solid organ injury

NN, Inc., (NASDAQ: NNBR) a diversified industrial company, today announced it has completed the acquisition of the assets of Bridgemedica, LLC (“Bridgemedica”), a medical device company that provides concept to supply solutions through design, development engineering and manufacturing.

he brightest minds in Alzheimer’s research are meeting in Las Vegas for the Global Alzheimer’s Platform Foundation’s GAP-Net Site Optimization Conference from Feb 21 - 23.